Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

BMY 56.11 -0.17 (-0.30%)
price chart
Bristol-Myers to buy Amylin for about $5.3 billion
NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Bristol-Myers in Deal for Amylin Valued at $7 Billion  New York Times (blog)
Bristol-Myers outbids Big Pharma pack and nabs Amylin for $5.3B  FierceBiotech
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Dying man fights to get experimental drug from Bristol-Myers Squibb
Darcy Doherty, 48, is dying of cancer and believes his last chance at life is an experimental drug that a pharmaceutical company refuses to give him. Doherty, shown with wife Rebecca at their Toronto home, is battling to get the firm to change its mind.
Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug
Law360, New York (June 21, 2012, 7:39 PM EDT) -- Bristol-Myers Squibb Co. on Thursday filed suit in Delaware federal court alleging Sandoz Inc.'s plan to make a generic version of the hepatitis B drug Baraclude would lead to infringement of BMS' patent ...
FDA Once Again Delays Approval Of Apixaban (Eliquis)
PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S.
ASCO: Paclitaxel Bests New Drugs in Breast Cancer
CHICAGO -- Patients with metastatic breast cancer did just as well -- and maybe better -- with paclitaxel-based chemotherapy compared with two newer, more expensive agents, results of a randomized trial showed.
Six-Year Follow-Up Data for SPRYCEL� (dasatinib) 100 mg Once Daily ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL� (dasatinib) in Philadelphia ...
AstraZeneca $4bn approach for diabetes specialist Amylin
For Astra, which on Sunday declined to comment, the purchase would enable it to replace sales lost on existing drugs when patent protection expires.
Insight: Top heart doctors fret over new blood thinners
Boehringer Ingelheim said it is working on an antidote, but declined to elaborate. Johnson & Johnson said it is not developing an antidote, but is monitoring early efforts by other drugmakers to come up with one.
Docs fret over new blood thinners  Free Malaysia Today